336 related articles for article (PubMed ID: 19038790)
1. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
2. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.
Sun H; Tsai Y; Nowak I; Liesveld J; Chen Y
Stem Cell Res; 2012 Sep; 9(2):77-86. PubMed ID: 22683680
[TBL] [Abstract][Full Text] [Related]
4. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
5. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist.
Stasi R
Expert Opin Drug Discov; 2009 Jan; 4(1):85-93. PubMed ID: 23480339
[TBL] [Abstract][Full Text] [Related]
7. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist.
Abe M; Suzuki K; Sakata C; Sugasawa K; Hirayama F; Koga Y; Kawasaki T; Naganuma S; Itoh H
Eur J Pharmacol; 2011 Jan; 650(1):58-63. PubMed ID: 20950606
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag.
Garnock-Jones KP; Keam SJ
Drugs; 2009; 69(5):567-76. PubMed ID: 19368418
[TBL] [Abstract][Full Text] [Related]
12. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
13. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
[TBL] [Abstract][Full Text] [Related]
14. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Quintino de Oliveira B; Catto LFB; Santana BAA; Tellechea MF; Scheucher PS; Scheinberg P; Calado RT
Br J Haematol; 2021 Apr; 193(2):410-414. PubMed ID: 33216370
[TBL] [Abstract][Full Text] [Related]
16. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.
Di Buduo CA; Currao M; Pecci A; Kaplan DL; Balduini CL; Balduini A
Haematologica; 2016 Dec; 101(12):1479-1488. PubMed ID: 27515246
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
Xie C; Zhao H; Bao X; Fu H; Lou L
J Cell Mol Med; 2018 Nov; 22(11):5367-5377. PubMed ID: 30156363
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
Baker JE; Su J; Koprowski S; Dhanasekaran A; Aufderheide TP; Gross GJ
J Pharmacol Exp Ther; 2015 Mar; 352(3):429-37. PubMed ID: 25512369
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
